Profile data is unavailable for this security.
About the company
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
- Revenue in USD (TTM)201.00k
- Net income in USD-28.05m
- Incorporated1990
- Employees26.00
- LocationAIM ImmunoTech Inc2117 SW Highway 484OCALA 34473-7949United StatesUSA
- Phone+1 (352) 448-7797
- Fax+1 (352) 480-4620
- Websitehttps://aimimmuno.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NKGen Biotech Inc | 0.00 | -88.25m | 11.27m | 63.00 | -- | -- | -- | -- | -3.74 | -3.74 | 0.00 | -2.71 | 0.00 | -- | -- | 0.00 | -480.25 | -- | -- | -- | -- | -- | -- | -- | -- | -0.4822 | -- | -- | -100.00 | -- | -210.06 | -- | -- | -- |
| Lyra Therapeutics Inc | 1.47m | -97.61m | 11.65m | 87.00 | -- | 0.5651 | -- | 7.92 | -1.51 | -1.51 | 0.0229 | 0.315 | 0.0148 | -- | -- | 16,715.91 | -97.94 | -58.01 | -118.22 | -68.69 | -- | -- | -6,635.76 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Viaderma Inc | 17.80m | 2.31m | 11.72m | 75.00 | 0.0006 | 0.00004 | 2.17 | 0.6585 | 16.84 | 16.84 | 129.62 | 255.59 | 0.4126 | 24.69 | 1.21 | 237,331.30 | 5.36 | -- | 6.53 | -- | 28.90 | -- | 12.99 | -- | 2.07 | 5.66 | 0.1718 | -- | -29.15 | -- | -40.70 | -- | -- | -- |
| Aspira Women's Health Inc | 8.92m | -15.95m | 11.73m | 64.00 | -- | -- | -- | 1.31 | -1.45 | -1.45 | 0.801 | -0.2892 | 1.53 | 15.11 | 5.79 | 139,421.90 | -273.16 | -110.58 | -3,758.30 | -151.88 | 57.84 | 45.23 | -178.80 | -334.08 | 0.5542 | -17,354.00 | -- | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 11.87m | 4.00 | -- | -- | -- | 15,824.20 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| Sol Gel Technologies Ltd | 11.71m | -9.57m | 12.29m | 36.00 | -- | 0.354 | -- | 1.05 | -0.3435 | -0.3435 | 0.4202 | 1.25 | 0.2522 | -- | 3.34 | 325,194.40 | -20.62 | -31.60 | -23.40 | -35.49 | -- | -- | -81.75 | -135.76 | -- | -- | 0.00 | -- | -59.98 | 64.50 | -82.52 | -- | -33.78 | -- |
| Sensei Biotherapeutics Inc | 0.00 | -29.80m | 12.53m | 28.00 | -- | 0.2736 | -- | -- | -1.19 | -1.19 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -44.18 | -47.03 | -48.36 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0222 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
| AIM ImmunoTech Inc | 201.00k | -28.05m | 12.74m | 26.00 | -- | 1.87 | -- | 63.39 | -0.5703 | -0.5703 | 0.004 | 0.1068 | 0.0082 | -- | 12.18 | 7,730.77 | -113.70 | -45.64 | -149.16 | -48.35 | 71.14 | -231.75 | -13,952.74 | -11,695.01 | -- | -- | 0.3018 | -- | 43.26 | -11.26 | -48.94 | -- | 35.73 | -- |
| HST Global Inc | 0.00 | -123.45k | 12.80m | 1.00 | -- | -- | -- | -- | -0.0209 | -0.0209 | 0.00 | -0.0004 | 0.00 | -- | -- | -- | -3,300.80 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -27.31 | 5.81 | -- | -- | -- | -0.7858 | -- | -- | -- |
| Inhibitor Therapeutics Inc | 0.00 | -3.08m | 12.92m | 3.00 | -- | 3.79 | -- | -- | -0.0179 | -0.0179 | 0.00 | 0.0198 | 0.00 | -- | -- | 0.00 | -38.42 | 27.48 | -38.90 | 32.70 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -125.39 | -- | -- | -- |
| NRX Pharmaceuticals Inc | 0.00 | -20.39m | 13.01m | 2.00 | -- | -- | -- | -- | -1.69 | -1.69 | 0.00 | -1.65 | 0.00 | -- | -- | -- | -231.96 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -104.47 | -- | -- | -- | -- | 24.14 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | 4.50m | 13.21m | 2.00 | 3.40 | 0.2782 | 2.94 | -- | 0.5058 | 0.5058 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | 35.90 | -7.42 | 38.19 | -7.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -299.38 | -- | -- | -- |
| Traws Pharma Inc | 226.00k | -140.79m | 13.58m | 16.00 | -- | -- | -- | 60.11 | -141.34 | -141.34 | 0.2473 | -0.6719 | 0.0126 | -- | 0.2113 | 14,125.00 | -782.70 | -63.43 | -1,568.46 | -85.72 | -- | -- | -62,294.25 | -3,257.92 | -- | -- | -- | -- | 0.00 | -28.72 | 0.0844 | -- | -- | -- |
| Cingulate Inc | 0.00 | -16.35m | 14.39m | 13.00 | -- | 1.13 | -- | -- | -70.83 | -70.83 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -168.10 | -- | -268.55 | -- | -- | -- | -- | -- | -- | -141.37 | 0.0007 | -- | -- | -- | -33.14 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to AIM ImmunoTech Inc's reporting currency: US Dollar USD
13.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Sep 2024 | 4.33m | 6.84% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.98m | 3.12% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 698.27k | 1.10% |
| Geode Capital Management LLCas of 30 Sep 2024 | 464.02k | 0.73% |
| Citadel Securities LLCas of 30 Sep 2024 | 457.77k | 0.72% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 243.21k | 0.38% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 173.10k | 0.27% |
| Verition Fund Management LLCas of 30 Sep 2024 | 153.00k | 0.24% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 85.12k | 0.13% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024 | 84.32k | 0.13% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
